Skip to main content
SYNAIRGEN PLC logo

SYNAIRGEN PLC — Investor Relations & Filings

Ticker · SNG ISIN · GB00B0381Z20 LEI · 213800IMMTOPPDF8HD24 IL Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2021-10-21 Major Shareholding Noti…
Country GB United Kingdom
Listing IL SNG

About SYNAIRGEN PLC

https://www.synairgen.com/

Synairgen PLC is a clinical-stage biotechnology company focused on the discovery and development of treatments for severe respiratory diseases. The company's primary focus is its lead investigative candidate, SNG001, an inhaled formulation of interferon-beta (IFN-β). SNG001 is being developed as a potential host-directed, broad-spectrum antiviral therapy delivered directly to the lungs. This approach aims to treat hospitalized patients with severe viral lung infections caused by a range of pathogens, including influenza, RSV, and coronaviruses.

Recent filings

Filing Released Lang Actions
Holdings in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled with 'RNS Number : 8748P' and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of a Major Shareholding Notification. The filing details the percentage of voting rights crossed or reached (13.396%) by Polygon Global Partners LLP and Reade Eugene Griffith. Although it is distributed via RNS, the specific content is a notification of a major holding change, making 'MRQ' (Major Shareholding Notification) the most accurate classification over the general 'RNS' fallback.
2021-10-21 English
Grant of Options
Remuneration Information Classification · 99% confidence The document is identified by the RNS Number (7334P) and explicitly states it is a 'Press Release' from Synairgen plc, dated 21 October 2021. The content details the 'Grant of options' to employees, including Persons Discharging Managerial Responsibilities (PDMRs), which constitutes insider trading or executive share transaction reporting. This directly aligns with the definition of Director's Dealing (DIRS). Although it is a regulatory announcement format (RNS), the specific subject matter (PDMR share transactions) makes DIRS the most precise classification over the general RNS fallback.
2021-10-21 English
SNG001 progresses to Phase 3 of ACTIV-2 trial
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 5946P' and is dated '20 October 2021'. It contains standard regulatory boilerplate language at the end, mentioning 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' The content itself is an announcement regarding a clinical trial update (SNG001 advancing to Phase 3 of the ACTIV-2 COVID-19 Trial). Since this is a general, time-sensitive regulatory announcement distributed via the RNS system that does not fit into the more specific categories like ER, DIV, or DIRS, it falls under the general Regulatory Filings category (RNS). The document length is moderate (5934 chars), but the primary identifier is the RNS header and footer, indicating a general regulatory news service release.
2021-10-20 English
Synairgen appoints Gareth Walters, Ph.D. as CRO
Board/Management Information Classification · 98% confidence The document is an official announcement released via RNS (RNS Number : 8677O) dated October 13, 2021. The core content announces the appointment of a new executive, Gareth Walters, Ph.D., as Chief Regulatory Officer. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific content is management-related, making MANG the most precise classification over the general RNS fallback.
2021-10-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to voting rights, share ownership thresholds, and notification dates to the FCA (Financial Conduct Authority). This structure is characteristic of regulatory filings concerning changes in significant shareholdings. The filing type 'TR-1' directly corresponds to the notification of major holdings, which falls under the category of Major Shareholding Notification (MRQ) in the provided definitions, as it details changes in ownership crossing a threshold (12.218% reported). Although it is a regulatory filing, MRQ is more specific than the general RNS fallback.
2021-10-05 English
Non-Executive Director Appointment
Board/Management Information Classification · 99% confidence The document begins with an 'RNS Number' and is dated 30 September 2021. The core content announces the 'appointment of Theodora Harold as an independent Non-Executive Director of the Company and Chair of the Audit Committee with immediate effect.' This directly relates to changes in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). Although it contains regulatory boilerplate text from RNS, the primary subject matter is the director appointment, not a general regulatory announcement (RNS) or a specific insider trade report (DIRS).
2021-09-30 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.